Yamada Yuji, Okubo Ryo, Tachimori Hisateru, Uchino Takashi, Kubota Ryotaro, Okano Hiroki, Ishikawa Shuhei, Horinouchi Toru, Takanobu Keisuke, Sawagashira Ryo, Hasegawa Yumi, Sasaki Yohei, Nishiuchi Motohiro, Kawashima Takahiro, Tomo Yui, Hashimoto Naoki, Ikezawa Satoru, Nemoto Takahiro, Watanabe Norio, Sumiyoshi Tomiki
Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Clinical Research & Education Promotion Division, National Center of Neurology and Psychiatry, Tokyo, Japan.
Front Psychol. 2022 Aug 3;13:878829. doi: 10.3389/fpsyg.2022.878829. eCollection 2022.
Social cognitive impairments adversely affect social functioning (e.g., employment status) in patients with schizophrenia. Although pharmacological interventions have been suggested to provide some benefits on social cognition, little information is available on the comparative efficacy of pharmacotherapy. Thus, the aim of this planned systematic review and network meta-analysis is to perform a quantitative comparison of the effects of various psychotropic drugs, including supplements, on social cognition disturbances of schizophrenia.
The literature search will be carried out using the PubMed, Embase, Cochrane Central Register of Controlled Trials, PsycINFO, ClinicalTrials.gov, and International Clinical Trials Registry Platform databases from inception onward. Randomized controlled trials that examined the efficacy of drugs in social cognitive disturbances will be included, based on the most recent studies and the broader literature than previously searched. This protocol defines the methods that will be used for study selection, data collection, quality assessment, and statistical syntheses.
The findings this work are expected to help promote the development of better therapeutics of social cognitive impairments in schizophrenia and related psychiatric conditions.
[www.crd.york.ac.uk/prospero], identifier [CRD42021293224].
社会认知障碍对精神分裂症患者的社会功能（如就业状况）产生不利影响。尽管已有研究表明药物干预对社会认知有一定益处，但关于药物治疗的相对疗效的信息却很少。因此，本计划中的系统评价和网状Meta分析的目的是对包括补充剂在内的各种精神药物对精神分裂症社会认知障碍的影响进行定量比较。
将从创刊起使用PubMed、Embase、Cochrane对照试验中央注册库、PsycINFO、ClinicalTrials.gov和国际临床试验注册平台数据库进行文献检索。将根据最新研究以及比之前检索范围更广的文献，纳入检验药物对社会认知障碍疗效的随机对照试验。本方案定义了将用于研究选择、数据收集、质量评估和统计合成的方法。
预期本研究结果将有助于推动针对精神分裂症及相关精神疾病中社会认知障碍的更好治疗方法的发展。
